MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Marinus Pharmaceuticals, Inc.

170 North Radnor Chester Road
Suite 250
Radnor, PA 19087
United States
484-801-4670
http://www.marinuspharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees36

Key Executives

NameTitlePayExercisedYear Born
Dr. Scott BraunsteinCEO & Director15.21kN/A1963
Mr. Edward F. SmithVP, CFO, Treasurer & Sec.501kN/A1971
Dr. Lorianne K. MasuokaChief Medical Officer501kN/A1961
Ms. Lisa M. CaperelliExec. Director of Investor & Strategic RelationsN/AN/AN/A
Mr. Thomas J. LyonsVP of Corp., Bus. Devel. & Commercial PlanningN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Corporate Governance

Marinus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.